EyePoint (EYPT) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed EyePoint (EYPT) over the past year, losing 17.0% versus a loss of 75.1%. Over five years, EYPT leads with a -69.8% price change compared with -75.4% for VNDA. EyePoint is the larger company by market cap ($285.1 million vs $276.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | VNDA |
|---|---|---|
| Share price | $3.40 | $4.57 |
| Market cap | $285.06M | $276.31M |
| 1-day change | -1.73% | +0.88% |
| YTD return | -81.06% | -48.64% |
| 1-year return | -75.07% | -17.03% |
| 5-year return | -69.76% | -75.39% |
| Forward P/E | — | 22.85 |
| EPS (TTM) | $-3.75 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.11 | $9.94 |
| 52-week low | $3.05 | $4.27 |
| Distance from 52-week high | -82.21% | -54.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +662.06% | +157.11% |
| Average volume | 3.96M | 974.13K |
| Shares outstanding | 83.84M | 60.46M |
| Employees | 214 | 533 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed EYPT by 58.0 percentage points over the past year.
- The two companies sit in different sectors: EyePoint in Industrials and Vanda Pharmaceuticals in Health Care.
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
EYPT vs VNDA FAQ
Which is bigger, EyePoint or Vanda Pharmaceuticals?
EyePoint (EYPT) is larger, with a market capitalization of $285.06M compared with $276.31M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, EYPT or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -75.07% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Vanda Pharmaceuticals in the same industry?
No. EyePoint is in the Industrials sector, while Vanda Pharmaceuticals is in Health Care.